TranScrip Partners opens Hong Kong office
08 October, 2013UK-headquartered contract organisation TranScrip Partners has opened a new office in Hong Kong. This follows recent openings in Australia and the US and is underpinned by the continuing increase of contracts in the Asia-Pacific region.
ResMed nominates new director
04 October, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) has nominated US health sector veteran Carol J Burt to take long-serving director Michael Quinn's place on the board once his final term expires.
Facing the challenges of the agriculture, food, water and energy nexus
03 October, 2013On the premise that by 2050 the world will have a population of nine billion people, the OECD has declared a need to address the energy, water, food and agriculture nexus. More than 100 people gathered recently to discuss the role of biotechnology in addressing these issues and opportunities in food production.
pSivida licensee expects NHS listing in November
02 October, 2013 by Dylan Bushell-EmblingThe UK's NICE has issued a final draft recommendation in favour of reimbursement for pSivida (ASX:PVA) licensee Alimera Sciences' Iluvien in a subgroup of DME patients.
AusBiotech members invited to vote for board
01 October, 2013Online voting for the 2013 AusBiotech board election ballot is now open. The board has two positions available for election.
Bioniche posts last results before animal health sale
30 September, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has reported its FY13 results and completed a Canadian equity offering and private placement to raise C$9.8m.
New CEO for Medical Technology Association of Australia
30 September, 2013The Medical Technology Association of Australia Limited has appointed Susanne Tegen as its new chief executive officer.
First Parkinson's patient implanted with LCT's NTCELL
27 September, 2013 by Dylan Bushell-EmblingThe first Parkinson's patient has been implanted with Living Cell Technologies' (ASX:LCT) NTCELL regenerative treatment during a phase I trial.
pSivida Q4 loss rises on phase III trial spending
26 September, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) attributed costs associated with initiating its phase III trial of Medidur in posterior uveitis for a 69% higher Q4 loss.
AusBiotech joins forces with Cook Medical and Deloitte on tax
26 September, 2013Biotechnology industry experts are joining forces to support a 'patent box' tax incentive, like that recently introduced on the UK, to keep home-grown IP in Australia and keep the local medical manufacturing industry globally competitive.
Allied's CardioCel stands the test of time
26 September, 2013 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) said paediatric heart defect patients treated using its CardioCel tissue patch have shown no sign of calcification at the site of repair after up to five years of monitoring.
iSonea launches AirSonea in Australia
25 September, 2013 by Dylan Bushell-EmblingiSonea's flagship AirSonea smartphone-compatible asthma wheeze monitoring device was launched in Australia today by gold medallist Cathy Freeman.
Vic govt offering grants for high-tech projects
25 September, 2013 by Dylan Bushell-EmblingThe Victorian Government has launched a new round of its Technology Implementation voucher program, giving the state's life science sector a chance to again take advantage of the opportunity.
Mesoblast spine trial to be presented at NASS meet
24 September, 2013 by Dylan Bushell-EmblingThe lead investigator for a trial of Mesoblast's (ASX:MSB) MPCs in spinal fusion procedures will present details from the study at next month's North American Spine Society meeting.
Innate Immunotherapeutics plans move across Tasman
24 September, 2013 by Susan WilliamsonNew Zealand biopharmaceutical company Innate Immunotherapeutics will migrate across the Tasman this month in a bid to get its Phase IIb trial financed and underway in Australia.
